1
|
Sarabi M, Perraud A, Mazouffre C, Nouaille M, Jauberteau MO, Mathonnet M. Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients. Biomed Rep 2016; 6:89-94. [PMID: 28123714 DOI: 10.3892/br.2016.801] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 09/08/2016] [Indexed: 12/11/2022] Open
Abstract
Previous studies have reported the association between brain-derived neurotrophic factor (BDNF) and tumor development in numerous cancers. However, the accurate implication of the two specific ligands of tropomyosin kinase B receptor, BDNF and neurotrophic factor 4 (NT4/5), has not been studied in colorectal cancer (CRC) patients. The present study investigated the significance of serum BDNF and the NT4/5 in association with the intake of psychoactive drugs in CRC patients. Soluble BDNF and NT4 in the serum were assessed by ELISA. Although no correlation of BDNF and NT4 with the CRC stage was identified, a positive correlation was found between NT4 and the intake of psychoactive drugs (P=0.0457). For BDNF, a correlation was found in particular with the intake of benzodiazepine (P=0.0221). As BDNF and NT4/5 are implicated in the response of psychoactive treatments applied to manage depression, which frequently occurs in cancer patients, they cannot be used as prognostic or diagnostic markers for CRC in these patients. However, high expression of BDNF and NT4 was significantly associated with better survival. Therefore, these NTs may be used as markers for monitoring depression or predicting survival in CRC patients.
Collapse
Affiliation(s)
- Matthieu Sarabi
- Department of Hepato-Gastro-Enterology, University of Limoges Teaching Hospital, F-87042 Limoges Cedex, France; Department of Medical Oncology, Léon Bérard Center, F-69008 Lyon, France
| | - Aurélie Perraud
- Department of Digestive, General and Endocrinal Surgery, University of Limoges Teaching Hospital, F-87042 Limoges Cedex, France; Laboratory EA 3842, Cellular Homeostasis and Pathologies, Medicine and Pharmacy Faculties, University of Limoges, F-87025 Limoges Cedex, France; CNRS 3503 Department, Federative Research Institute, Genomic, Environment, Immunity, Health and Therapeutics, University of Limoges, F-87025 Limoges Cedex, France
| | - Clément Mazouffre
- Laboratory EA 3842, Cellular Homeostasis and Pathologies, Medicine and Pharmacy Faculties, University of Limoges, F-87025 Limoges Cedex, France; CNRS 3503 Department, Federative Research Institute, Genomic, Environment, Immunity, Health and Therapeutics, University of Limoges, F-87025 Limoges Cedex, France
| | - Michelle Nouaille
- Department of Digestive, General and Endocrinal Surgery, University of Limoges Teaching Hospital, F-87042 Limoges Cedex, France
| | - Marie-Odile Jauberteau
- Department of Digestive, General and Endocrinal Surgery, University of Limoges Teaching Hospital, F-87042 Limoges Cedex, France; Laboratory EA 3842, Cellular Homeostasis and Pathologies, Medicine and Pharmacy Faculties, University of Limoges, F-87025 Limoges Cedex, France; CNRS 3503 Department, Federative Research Institute, Genomic, Environment, Immunity, Health and Therapeutics, University of Limoges, F-87025 Limoges Cedex, France
| | - Muriel Mathonnet
- Department of Digestive, General and Endocrinal Surgery, University of Limoges Teaching Hospital, F-87042 Limoges Cedex, France; Laboratory EA 3842, Cellular Homeostasis and Pathologies, Medicine and Pharmacy Faculties, University of Limoges, F-87025 Limoges Cedex, France; CNRS 3503 Department, Federative Research Institute, Genomic, Environment, Immunity, Health and Therapeutics, University of Limoges, F-87025 Limoges Cedex, France
| |
Collapse
|
2
|
Rudisill TM, Zhu M, Kelley GA, Pilkerton C, Rudisill BR. Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review. ACCIDENT; ANALYSIS AND PREVENTION 2016; 96:255-270. [PMID: 27569655 PMCID: PMC5045819 DOI: 10.1016/j.aap.2016.08.001] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Revised: 06/17/2016] [Accepted: 08/02/2016] [Indexed: 05/31/2023]
Abstract
OBJECTIVES Driving under the influence of prescription and over-the-counter medication is a growing public health concern. A systematic review of the literature was performed to investigate which specific medications were associated with increased risk of motor vehicle collision (MVC). METHODS The a priori inclusion criteria were: (1) studies published from English-language sources on or after January 1, 1960, (2) licensed drivers 15 years of age and older, (3) peer-reviewed publications, master's theses, doctoral dissertations, and conference papers, (4) studies limited to randomized control trials, cohort studies, case-control studies, or case-control type studies (5) outcome measure reported for at least one specific medication, (6) outcome measure reported as the odds or risk of a motor vehicle collision. Fourteen databases were examined along with hand-searching. Independent, dual selection of studies and data abstraction was performed. RESULTS Fifty-three medications were investigated by 27 studies included in the review. Fifteen (28.3%) were associated with an increased risk of MVC. These included Buprenorphine, Codeine, Dihydrocodeine, Methadone, Tramadol, Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, Carisoprodol, Zolpidem, and Zopiclone. CONCLUSIONS Several medications were associated with an increased risk of MVC and decreased driving ability. The associations between specific medication use and the increased risk of MVC and/or affected driving ability are complex. Future research opportunities are plentiful and worthy of such investigation.
Collapse
Affiliation(s)
- Toni M Rudisill
- Department of Epidemiology, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA; Injury Control Research Center, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA.
| | - Motao Zhu
- Department of Epidemiology, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA; Center for Injury Research and Policy, The Research Institute at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA; Injury Control Research Center, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA.
| | - George A Kelley
- Department of Biostatistics, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA.
| | - Courtney Pilkerton
- Department of Epidemiology, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA.
| | | |
Collapse
|
3
|
Koven NS, Collins LR. Urinary brain-derived neurotrophic factor as a biomarker of executive functioning. Neuropsychobiology 2015; 69:227-34. [PMID: 24942240 DOI: 10.1159/000362242] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2013] [Accepted: 03/17/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND/AIMS Neurotrophins such as brain-derived neurotrophic factor (BDNF) are vital for neuronal survival and adaptive plasticity. With high BDNF gene expression in the prefrontal cortex, BDNF is a potential regulatory factor for building and maintaining cognitive reserves. Recent studies suggest that individual differences in executive functioning, a broad cognitive domain reliant upon frontal lobe structure and function, are governed in part by variance in BDNF polymorphisms. However, as neurogenetic data are not necessarily indicative of in vivo neurochemistry, this study examines the relationship between executive functioning and the neurotransmitter by measuring peripheral BDNF levels. METHODS Fifty-two healthy young adults completed a battery of standardized executive function tests. BDNF levels, adjusted for creatinine, were quantified with enzyme-linked immunosorbent assay of urine samples taken at the time of testing. RESULTS BDNF concentration was positively associated with cognitive flexibility but had no relationship with working memory, abstract reasoning/planning, self-monitoring/response inhibition, or fluency. CONCLUSIONS These results individuate cognitive flexibility as the specific facet of executive functioning associated with in vivo BDNF levels. This study also validates urinary BDNF as a peripheral biomarker of cognition in healthy adults.
Collapse
Affiliation(s)
- Nancy S Koven
- Program in Neuroscience, Department of Psychology, Bates College, Lewiston, Maine, USA
| | | |
Collapse
|
4
|
Tamashiro LF, Oliveira RDR, Oliveira R, Frota ERC, Donadi EA, Del-Ben CM, Teixeira AL, Louzada-Junior P. Participation of the neutrophin brain-derived neurotrophic factor in neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 2014; 53:2182-90. [PMID: 24942492 DOI: 10.1093/rheumatology/keu251] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
OBJECTIVE Brain-derived neurotrophic factor (BDNF) is associated with the pathogenesis of several neuropsychiatric (NP) diseases, but there are few studies involving SLE. The aim of this study was to investigate whether plasma BDNF levels are associated with disease activity in SLE patients with severe NPSLE and non-NPSLE manifestations. METHODS We assessed 131 SLE patients and 24 randomly selected healthy individuals. SLE patients were evaluated in a cross-sectional study allocated according to the presence or not of NP manifestations and disease activity: (i) active NPSLE (n = 40), (ii) inactive NPSLE (n = 26), (iii) active SLE (n = 29) and (iv) inactive SLE (n = 36). In addition, NPSLE patients (n = 40) were evaluated before and after treatment. Disease activity was assessed according to the SLEDAI score. The plasma BDNF was measured by ELISA. RESULTS BDNF levels were increased in inactive NPSLE when compared with active SLE and controls (P < 0.0001). We observed similar findings in inactive SLE when compared with active SLE (P < 0.0001). In addition, we found an inverse correlation between plasma BDNF levels and the SLEDAI (r = -0.54, P < 0.0001) and a positive correlation with complement levels. We also observed an increase in BDNF levels in parallel with the improvement in NP symptoms. CONCLUSION Plasma BDNF level is increased in SLE patients and this increase is independent of the occurrence of NP manifestations. In addition, plasma BDNF levels increased with control of SLE activity, which points to the potential use of BDNF as a biomarker of response to treatment.
Collapse
Affiliation(s)
- Leticia Faleiros Tamashiro
- Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Renê D R Oliveira
- Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Rodrigo Oliveira
- Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Elizabeth Regina Comini Frota
- Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Eduardo Antonio Donadi
- Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Cristina Marta Del-Ben
- Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Antonio Lucio Teixeira
- Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Paulo Louzada-Junior
- Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. Division of Clinical Immunology, School of Medicine of Ribeirão Preto, Center for Research in Inflammatory Diseases, University of São Paulo, São Paulo, Neurology Unit, University Hospital, Federal University of Minas Gerais, Minas Gerais and Division of Psychiatry, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
| |
Collapse
|
8
|
Köhler S, Klimke S, Hellweg R, Lang UE. Serum brain-derived neurotrophic factor and nerve growth factor concentrations change after alcohol withdrawal: preliminary data of a case-control comparison. Eur Addict Res 2013; 19:98-104. [PMID: 23128606 DOI: 10.1159/000342334] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2012] [Accepted: 08/05/2012] [Indexed: 01/01/2023]
Abstract
BACKGROUND Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are involved in neuroadaptation and foster survival of central and peripheral neurons. In this study, we addressed the question whether BDNF and NGF serum concentrations change during subacute alcohol withdrawal in patients with alcohol dependence compared to healthy controls. METHODS Fifteen patients (age 48.6 ± 7 years) and 15 healthy age-matched controls (age 48.8 ± 7 years) participated consecutively in a 2-week withdrawal study. RESULTS Mean BDNF levels (7.8 ng/ml, IQR = 4.4-10.7 vs. 16.5 ng/ml, IQR = 13.9-25.6; Z = -3.8, p < 0.0001) and NGF levels (5.8 pg/ml, IQR = 3.8-13.0 vs. 18.4 pg/ml, IQR = 10.9-25.1; Z = -2.5, p = 0.012) were significantly decreased in alcohol-dependent subjects when compared to healthy matched controls. NGF concentrations decreased significantly from day 3 to day 14 (Z = -2.36; p = 0.019). Mean BDNF concentrations showed a tendency to increase after withdrawal from day 3 to day 14 (Z = 1.7; p = 0.078). CONCLUSION Decreased NGF and BDNF concentrations in patients suffering from alcohol dependence, which stabilize after physical withdrawal, are in line with withdrawal symptoms and neurological risk factors. In turn, increase of BDNF after acute withdrawal might be connected to neurobiological and behavioral stabilization.
Collapse
Affiliation(s)
- Stephan Köhler
- Department of Psychiatry and Psychotherapy, Charité Medicine Berlin, Campus Mitte, Berlin, Germany
| | | | | | | |
Collapse
|